Litcius/Paper detail

High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial

Jiayi Yu, Leilei Jiang, Lina Zhao, Xue Yang, Xiaomin Wang, Dan Yang, Minglei Zhuo, Hanxiao Chen, Wei Huang, Zhengfei Zhu, Min Zhang, Yipeng Song, Quanfu Li, Zhanshu Ma, Qifeng Wang, Yanli Qu, Rong Yu, Huiming Yu, Jun Zhao, Anhui Shi, Anhui Shi, Anhui Shi, Jiayi Yu, Leilei Jiang, Lina Zhao, Xue Yang, Xiaomin Wang, Dan Yang, Minglei Zhuo, Hanxiao Chen, Wei Huang, Zhengfei Zhu, Min Zhang, Yipeng Song, Quanfu Li, Zhanshu Ma, Qifeng Wang, Yanli Qu, Rong Yu, Huiming Yu, Li Chu, Yun Bai, Yidian Zhao, Jinghua Luo, WenLi Chen, Tao Gu, Shixin Liu, Jun Yang, Yiqun Wu, Jun Zhao, Jun Zhao, Anhui Shi, Anhui Shi

2024The Lancet Respiratory Medicine37 citationsDOI

Topics & Concepts

MedicineRadiation therapyLung cancerOncologyStage (stratigraphy)Dose fractionationChemotherapyProphylactic cranial irradiationInternal medicineNuclear medicineRadiologyPaleontologyBiologyMyocardial infarctionConventional PCILung Cancer Research StudiesLung Cancer Treatments and MutationsNeuroendocrine Tumor Research Advances
High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial | Litcius